Webcast Alert: Aethlon Medical, Inc. Presentation at Informed Investors Security and Defense Virtual Stocks Forum to be Webcast

Webcast Alert: Aethlon Medical, Inc. Presentation at Informed
Investors Security and Defense Virtual Stocks Forum to be Webcast on Thursday,
July 29, 2004, 10:00 am ET 


LA JOLLA, Calif., July 27  /PRNewswire/ -- Aethlon Medical, Inc. (OTC:AEMD)
(BULLETIN BOARD: AEMD)  will present at the following forum:

  What:     Aethlon Medical, Inc. (OTC:AEMD) (BULLETIN BOARD: AEMD)  will give
a
            presentation at Informed Investors Security and Defense Virtual
            Stocks Forum.

            Additional presenting companies include: TASER International,
            IPIX Corp., Isis Pharmaceuticals and Law Enforcement Associates,
            Inc.

            Forum keynotes will be delivered by Jack Mallon, Founder of
            Mallon & Associates, at 9 am and Kevin Skislock, Partner & CEO,
            Laguna Research Partners, at 9:30 am.

  When:     July 29, 2004 @ 10:00 AM Eastern Time

  Where:    http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85120

  How:      Live over the Internet -- Simply log on to the web at the
            address above.

  Contact:  James A. Joyce, Chief Executive Officer, 



If you are unable to attend the live event, the forum will be available via
webcast at http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85120.

Aethlon Medical is pioneering the development of viral filtration devices that
rapidly reduce the presence of infectious disease and toxins in the body.
Aethlon has published compelling human blood studies of the Hemopurifier(TM) to
treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it
is developing pathogen filtration devices to treat infectious agents used in
biological warfare and terrorism. The Hemopurifier is a proprietary platform
technology that converges the established scientific principles of affinity
chromatography and hemodialysis as a means to augment the immune response of
clearing viruses and toxins from the blood before cell and organ infection can
occur. On March 4, 2004, Aethlon announced a cooperative agreement with the
National Center for Biodefense (NCBD) at George Mason University.  Under the
agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin
filtration devices designed to protect the lives of U.S. Military personnel
exposed to infectious agents as a result of biological warfare. For additional
information, visit the company's Web site at http://www.aethlonmedical.com/.

FORUM CONTACT:  Cary Loeser, Informed Investors, 804-327-3407, 

Web site:  http://www.informedinvestors.com 

DATASOURCE: Aethlon Medical, Inc.



CONTACT:  James A. Joyce, Chief Executive Officer of Aethlon Medical,

Inc., , or Cary Loeser, Informed Investors,

[phone], 



Web site:  http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85120

http://www.aethlonmedical.com/

http://www.informedinvestors.com/ 

Copyright